Post-POBA CABG Recommendation
For patients undergoing CABG after plain balloon angioplasty (POBA), proceed with surgery without delay since POBA does not involve stent placement or mandatory dual antiplatelet therapy—the primary concern is optimizing perioperative antiplatelet and statin management rather than timing.
Key Distinction: POBA vs. Stent-Based PCI
Plain balloon angioplasty differs fundamentally from stent placement because it does not require prolonged dual antiplatelet therapy (DAPT). The timing concerns that dominate post-stent CABG discussions are largely irrelevant here. Your focus should be on perioperative medication management.
Perioperative Antiplatelet Management
Aspirin Strategy
- Continue aspirin through surgery if the patient is already taking it 1
- If not on aspirin preoperatively, initiate 100-325 mg within 6 hours postoperatively and continue indefinitely 2
- Aspirin significantly improves saphenous vein graft (SVG) patency, particularly in the first postoperative year 2
- Dosing between 100-325 mg daily appears equally efficacious 2
P2Y12 Inhibitor Management (if applicable)
If the patient received clopidogrel, prasugrel, or ticagrelor during or after POBA:
Pre-operative interruption timing 1:
- Clopidogrel: Stop 5 days before surgery (though recent data suggests 3 days may be sufficient 3)
- Prasugrel: Stop 7 days before surgery
- Ticagrelor: Stop 3-5 days before surgery
Post-operative resumption:
- Resume P2Y12 inhibitor within 24 hours after surgery 1
- Delay if post-CABG thrombocytopenia develops (platelet count <50,000/μL) 1
Important Caveat on Clopidogrel Timing
Recent high-quality data from 2024 analyzing 148,317 CABG patients shows that waiting 3 days after clopidogrel discontinuation yields comparable mortality and reexploration rates to waiting 5 days, while reducing preoperative length of stay 3. The adjusted odds of operative mortality and mediastinal reexploration plateau after day 3 3. However, blood product utilization remains elevated even at 5 days 3.
Mandatory Statin Therapy
All patients undergoing CABG must receive statin therapy unless contraindicated (Class I recommendation) 2:
- Target LDL <100 mg/dL with at least 30% reduction 2
- For very high-risk patients, target LDL <70 mg/dL 2
- For urgent/emergency CABG in statin-naïve patients, initiate high-dose statin immediately 2
- Never discontinue statins before or after CABG (Class III: Harm) 2
Post-CABG Long-Term Management
Antiplatelet Therapy
- Aspirin indefinitely (or clopidogrel 75 mg daily if aspirin-intolerant) 2
- Evidence for routine dual antiplatelet therapy post-CABG remains controversial 4, 5, 6
- Consider DAPT in select high-risk patients or those undergoing off-pump CABG 5
Additional Secondary Prevention
- Continue statin therapy indefinitely 2, 6
- Beta-blockers and ACE inhibitors may benefit specific subgroups (e.g., reduced ejection fraction, hypertension) 6
Common Pitfalls to Avoid
Do not delay CABG unnecessarily in POBA patients waiting for arbitrary antiplatelet washout periods—unlike stent patients, there is no thrombosis risk from the intervention itself
Do not stop statins perioperatively—this increases adverse outcomes 2
Do not wait 48+ hours to initiate aspirin postoperatively—the SVG patency benefit is lost when aspirin starts >48 hours after surgery 2
Do not assume all post-PCI patients need the same CABG timing—POBA patients without stents can proceed more quickly than those with recent stent placement
Avoid routine platelet function testing—it adds cost without clear benefit except possibly in patients recently started on P2Y12 inhibitors 1